

Sex differences in clinical characteristics and long-term outcome in patients with heart failure: data from the KorAHF registry

Hye Mee Kim^{1,*}, Hack-Lyoung Kim^{2,*}, Myung-A Kim², Hae-Young Lee³, Jin Joo Park⁴, Dong-Ju Choi⁴, and on the behalf of the KorAHF Investigators[†]

¹Division of Cardiology, Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul;




²Division of Cardiology, Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul; ³Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul;

⁴Cardiovascular Center and Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

*These authors contributed equally to this manuscript.

[†]KorAHF Investigators are listed in acknowledgments.

Sex differences in clinical characteristics and long-term outcome in patients with heart failure: Data from the KorAHF registry

Prospective multi-center registry database						
		Age	Symptom (NYHA)	Preserved ejection fraction	Cardiovascular death	HF re-admission and death
 <p>5,625 Korean patients hospitalized for acute heart failure</p>	 Women (n = 2,632)	71.4 ± 13.8	II 13.9% III 36.5% IV 49.6%	33.2%	1 (ref)	1 (ref)
	 Men (n = 2,993)	65.9 ± 14.5	II 16.3% III 37.2% IV 46.4%	18.2%	HR 1.38	HR 1.13
		P < 0.001	P = 0.013	P < 0.001	P = 0.014	P = 0.030

Conclusion

In the Korean multi-center registry, despite having better clinical characteristics, men exhibited a higher risk of all-cause mortality and readmission for HF. The main cause of these disparities was the higher cardiovascular mortality rate observed in men compared to women with HFREF.

Background/Aims: Sex differences in the prognosis of heart failure (HF) have yielded inconsistent results, and data from Asian populations are even rare. This study aimed to investigate sex differences in clinical characteristics and long-term prognosis among Korean patients with HF.

Methods: A total of 5,625 Korean patients hospitalized for acute HF were analyzed using a prospective multi-center registry

database. Baseline clinical characteristics and long-term outcomes including HF readmission and death were compared between sexes.

Results: Women were older than men and had worse symptoms with higher N-terminal pro B-type natriuretic peptide levels. Women had a significantly higher proportion of HF with preserved ejection fraction (HFpEF). There were no significant differences in in-hospital mortality and rate of guideline-directed medical therapies in men and women. During median follow-up of 3.4 years, cardiovascular death (adjusted hazard ratio [HR], 1.38; 95% confidence interval [CI], 1.07–1.78; $p = 0.014$), and composite outcomes of death and HF readmission (adjusted HR, 1.13; 95% CI, 1.01–1.27; $p = 0.030$) were significantly higher in men than women. When evaluating heart failure with reduced ejection fraction (HFrEF) and HFpEF separately, men were an independent risk factor of cardiovascular death in patients with HFrEF. Clinical outcome was not different between sexes in HFpEF.

Conclusions: In the Korean multi-center registry, despite having better clinical characteristics, men exhibited a higher risk of all-cause mortality and readmission for HF. The main cause of these disparities was the higher cardiovascular mortality rate observed in men compared to women with HFrEF.

Keywords: Heart failure; Mortality; Prognosis; Sex difference; Women

INTRODUCTION

Population aging is a global phenomenon, and heart failure (HF) is a predominant disease of the elderly with an increased prevalence in old age. As a result, the absolute number of patients with HF is constantly growing [1], which constitutes a significant portion of the global disease burden [2].

Efforts have been made to understand the difference between men and women in various cardiovascular diseases and apply this knowledge to diagnosis and treatment. HF is one of the representative cardiovascular diseases that exhibit significant sex differences [3]. Several differences between men and women have been reported in HF, such as prevalence, risk factors, pathophysiology, and clinical presentation [3–6]. However, the findings regarding sex differences in HF prognosis remain inconclusive [7–9]. Some studies reported better survival in women with HF compared to men [7,10–13], while others demonstrated similar rates of mortality following admission for acute HF between men and women [8,14]. Meanwhile, a Japanese observational study on HF with preserved ejection fraction (HFpEF) demonstrated that elderly women were independently associated with worse clinical outcomes [15]. Additionally, research on the prognosis of HF based on sex has primarily been carried out in Western societies, with insufficient data on outcomes for Asians. Previously, we published data on the sex-specific prognosis of patients with acute HF using nationwide registry data [16]. In this study of 2,572 patients hospitalized

due to HF, there was no sex difference in long-term clinical outcomes. However, this data was from the registry constructed between 2004 and 2009. It does not reflect more recent contemporary clinical practice.

Identifying differences in the clinical features and prognosis of HF between men and women can enhance our understanding of the disease, and improve its management and prognosis of HF. It is also crucial to gather more data specific to the Asian population. Therefore, the objective of this study was to assess sex differences in characteristics and long-term clinical outcomes in Korean patients with HF, using a prospective cohort registry.

METHODS

Study population

The Korean Acute Heart Failure (KorAHF) registry is a prospective and multi-center cohort study conducted in Korea [17]. Briefly, patients who had symptoms or signs of HF and met one of the following criteria were consecutively enrolled on admission for acute decompensated HF: 1) pulmonary congestion or 2) objective findings of left ventricular (LV) systolic dysfunction or structural heart disease. Lung congestion was defined as ‘congestion’ on a chest X-ray or as rales on physical examination. Structural heart disease was defined as heart disease that involve cardiac valves, walls, chambers, or walls. There are no exclusion criteria. From

Table 1. Clinical characteristics at the time of admission

Characteristic	Total (n = 5,625)	Men (n = 2,993)	Women (n = 2,632)	p value
Age, yr	68.5 ± 14.5	65.9 ± 14.5	71.4 ± 13.8	< 0.001
Height, cm	160.4 ± 9.5	166 ± 6	152 ± 6	< 0.001
Weight, kg	60.3 ± 13.0	65.8 ± 12.4	54.0 ± 10.5	< 0.001
Body mass index, kg/m ²	23.3 ± 3.9	23.5 ± 3.7	23.0 ± 4.0	< 0.001
Systolic blood pressure, mmHg	131.2 ± 30.3	129 ± 30	133 ± 30	< 0.001
Diastolic blood pressure, mmHg	78.6 ± 18.7	78.3 ± 19.0	78.8 ± 18.3	0.277
Pulse pressure, mmHg	52.6 ± 21.3	51.0 ± 20.6	54.4 ± 21.8	< 0.001
Heart rate, beat per minute	92.6 ± 25.9	92.1 ± 26.0	93.1 ± 25.8	0.137
Dyspnea NYHA Fc grade				0.013
II	855 (15.2)	489 (16.3)	366 (13.9)	
III	2,074 (36.9)	1,114 (37.2)	960 (36.5)	
IV	2,696 (47.9)	1,390 (46.4)	1,306 (49.6)	
Comorbidities				
Hypertension	3,325 (59.1)	1,689 (56.4)	1,636 (62.2)	< 0.001
Diabetes mellitus	1,986 (35.3)	1,080 (36.1)	906 (34.4)	0.193
Ischemic heart disease	1,587 (28.2)	951 (31.8)	636 (24.2)	< 0.001
Dilated cardiomyopathy	473 (8.4)	284 (9.5)	189 (7.2)	0.002
Valvular heart disease	808 (14.4)	343 (11.5)	465 (17.7)	0.155
Atrial fibrillation	1,602 (28.5)	824 (27.5)	778 (29.6)	0.093
Chronic obstructive pulmonary disease	633 (11.3)	411 (13.7)	222 (8.4)	< 0.001
Chronic kidney disease	805 (14.3)	488 (16.3)	317 (12.0)	< 0.001
Malignancy	467 (8.3)	251 (8.4)	216 (8.2)	0.808
Cigarette smoking				< 0.001
None	3,452 (61.4)	1,019 (34.0)	2,433 (92.4)	
Ex-smoker	1,180 (21.0)	1,094 (36.6)	85 (3.3)	
Current smoker	993 (17.7)	880 (29.4)	113 (4.3)	
Alcohol drinking				< 0.001
None	3,468 (61.7)	1,184 (39.6)	2,284 (86.8)	
Social	1,786 (31.8)	1,463 (48.9)	323 (12.3)	
Heavy	371 (6.6)	346 (11.6)	25 (0.9)	
Laboratory findings				
White blood cell count, per μ L	8,674.4 ± 4,081.3	8,776.6 ± 4,231.7	8,558.1 ± 3,900.6	0.045
Hemoglobin, g/dL	12.4 ± 2.3	13.0 ± 2.4	11.7 ± 1.9	< 0.001
Glucose, mg/dL	155.4 ± 76.9	152.2 ± 73.4	159.1 ± 80.6	< 0.001
Glycated hemoglobin, %	6.7 ± 1.4	6.8 ± 1.4	6.7 ± 1.3	0.220
Total cholesterol, mg/dL	151.6 ± 43.2	147.7 ± 41.6	156.1 ± 44.5	< 0.001
High-density lipoprotein cholesterol, mg/dL	41.5 ± 13.9	40.3 ± 13.7	42.8 ± 13.9	< 0.001
Triglyceride, mg/dL	99.4 ± 59.1	96.8 ± 57.9	102.6 ± 60.2	0.007
Uric acid, mg/dL	7.1 ± 2.9	7.3 ± 2.9	6.7 ± 2.8	< 0.001
Creatinine, mg/dL	1.5 ± 1.5	1.7 ± 1.7	1.3 ± 1.2	< 0.001
Estimated GFR, mL/min/1.73 m ²	61.8 ± 32.9	62.9 ± 33.1	60.3 ± 32.4	0.003

Table 1. Continued

Characteristic	Total (n = 5,625)	Men (n = 2,993)	Women (n = 2,632)	p value
Sodium, mEq/L	137.5 ± 4.8	137.5 ± 4.7	137.5 ± 5.0	0.736
Potassium, mEq/L	4.4 ± 0.7	4.4 ± 0.7	4.3 ± 0.7	< 0.001
C-reactive protein, mg/dL	2.3 ± 4.2	2.5 ± 4.3	2.1 ± 3.9	0.01
NT-proBNP, pg/mL	9239.6 ± 10802.4	8,434.3 ± 10,184.7	10,139.1 ± 11,389.5	< 0.001
Echocardiographic findings				
LV-EDD, mm	57.4 ± 10.1	60.1 ± 10.0	54.4 ± 9.4	< 0.001
LV-EDD/BSA, mm/m ²	35.7 ± 6.7	34.9 ± 6.3	36.6 ± 7.1	< 0.001
LV-EDV, mL	152.5 ± 72.9	172.4 ± 75.4	129.4 ± 62.5	< 0.001
LV-EDV/BSA, mL/m ²	94.2 ± 43.6	100.0 ± 43.0	87.4 ± 43.3	< 0.001
LV-EF, %	37.8 ± 15.6	34.7 ± 14.6	41.2 ± 15.8	< 0.001
LA volume index, mL/m ²	63.7 ± 42.0	61.7 ± 37.5	65.8 ± 46.3	< 0.001
E wave velocity, m/s	0.9 ± 0.4	0.9 ± 0.4	1.0 ± 0.4	< 0.001
A wave velocity, m/s	0.7 ± 0.4	0.7 ± 0.4	0.8 ± 0.4	< 0.001
E/A ratio	1.6 ± 3.7	1.7 ± 3.1	1.5 ± 4.3	0.037
Deceleration time, ms	170.0 ± 82.1	163 ± 75	177 ± 89	< 0.001
e' velocity, cm/s	5.0 ± 2.3	5.1 ± 2.1	4.9 ± 2.5	0.031
a' velocity, cm/s	6.1 ± 2.8	6.0 ± 2.7	6.3 ± 2.8	0.017
s' velocity, cm/s	5.1 ± 2.0	5.0 ± 2.0	5.1 ± 1.9	0.226
E/e' ratio	21.2 ± 11.5	20.4 ± 11.4	22.1 ± 11.5	< 0.001
Tricuspid regurgitation Vmax, m/s	5.1 ± 2.0	5.0 ± 2.0	5.1 ± 1.9	0.175
Pulmonary artery systolic pressure, mmHg	43.9 ± 15.1	43.8 ± 15.4	44.0 ± 14.7	0.584

Values are presented as mean ± standard deviation or number (%).

BSA, body surface area; EDD, end diastolic dimension; EDV, end diastolic volume; EF, ejection fraction; GFR, glomerular filtration rate; LA, left atrium; LV, left ventricular; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association.

March 2011 to February 2014, 5,625 patients were enrolled in 10 tertiary university hospitals in Korea. The study was carried out following the principles of the Declaration of Helsinki, and written informed consent was obtained before enrollment. In addition, all study protocols for the registry constrictor were reviewed and approved by the Institutional Review Board (IRB) of each participating hospital. The IRB number for this study was 07-2023-15, which was obtained at Boramae Medical Center (Seoul, Korea).

Data collection

Body mass index (BMI) was calculated as weight (kg) divided by the square of the height (m²). Systolic and diastolic blood pressures (SBP and DBP) were measured using an oscillometric device. Hypertension was defined based on a previous diagnosis, current use of anti-hypertensive medications, or SBP/DBP ≥ 140/90 mmHg. Diabetes mellitus was defined based on a previous diagnosis, current use of anti-diabetic

medications, or fasting glucose ≥ 126 mg/dL. Transthoracic echocardiography was performed on all patients upon admission to assess cardiac function. LV end diastolic dimension and volume, LV end systolic diastolic dimension and volume, LV-EF, and diastolic parameters including mitral annular e' velocity, E/e', left atrium (LA) volume index, and peak TR velocity based on current diastolic function guideline [18] were collected. HF with reduced EF (HFrEF) was defined when the LV-EF was ≤ 40%, HF with mildly reduced EF (HFmrEF) was considered when LV-EF was 41–49%, and HFpEF was considered when LV-EF was ≥ 50%. Information about patient demographics, laboratory test results, electrocardiogram, echocardiography, medications, hospital course, and outcomes was collected at admission, at discharge, and events including mortality and rehospitalization for HF aggravation were recorded after discharge. Follow-up data were collected from patients by the attending physician at 30 days and 3, 6, 12, 24, 36, 48, and 60 months

after discharge.

Outcome measures

Clinical outcomes, including in-hospital mortality, readmission for worsening HF, cardiovascular death, and all-cause death, were documented in the KorAHF registry. Cardiovascular death was defined as deaths resulting from HF, stroke, sudden cardiac death, or other cardiovascular causes. The present study used a composite of all-cause death and readmission for HF as the primary outcome. Data on clinical events were obtained from hospital records reported by physicians, telephone contacts. In addition, the outcome data for patients lost to follow-up were collected from the National Death Records. Almost all Koreans (97%) are enrolled in the National Health Insurance Service (NHIS), and if a death is registered, crucial information, including the occurrence and precise timing of the death, can be retrieved from the NHIS database.

Statistical analyses

Baseline characteristics are described as numbers and percentages for categorical variables and mean \pm standard deviation for continuous variables. Patient characteristics were

compared between groups using a chi-square test for categorical variables, and a Student's t-test for continuous variables. Event-free survival analyses were conducted using the Kaplan–Meier method with log-rank testing and Cox proportional hazard modeling. Cox proportional hazard models were also used to generate event-free survival plots. Univariable and multivariable Cox regression models were estimated for the death, HF readmission, and composite outcomes. For each variable, an unadjusted hazard ratio (HR) was calculated, and multivariable models were produced based on a list of significant parameters ($p < 0.05$) at univariable analysis. The missing value was separately designated and excluded from the valid analysis cases. All statistical analyses were performed using SPSS version 22.0 (IBM Corp., Armonk, NY, USA) and R programming software version 4.2.2 (The R Foundation for Statistical Computing, Vienna, Austria). Statistical significance was set at $p < 0.05$.

RESULTS

Baseline characteristics

The study population had a mean age of 68.5 ± 14.5 years,

Table 2. Heart failure related characteristics

Characteristic	Total (n = 5,625)	Men (n = 2,993)	Women (n = 2,632)	p value
Heart failure type				< 0.001
HF _r EF (LVEF, \leq 40%)	3,252 (57.8)	1,972 (65.8)	1,280 (48.6)	
HF _{mr} EF (LVEF, 41–49%)	799 (14.2)	390 (13.0)	409 (15.5)	
HF _p EF (LVEF, \geq 50%)	1,363 (24.2)	524 (17.5)	839 (31.9)	
New onset heart failure				0.014
De novo heart failure	2,936 (52.2)	1,608 (53.7)	1,328 (50.5)	
Acute decompensated heart failure	2,689 (47.8)	1,385 (46.3)	1,304 (49.5)	
Pulmonary edema	1,067 (19.0)	545 (18.2)	522 (19.8)	0.121
Cardiogenic shock	214 (3.8)	133 (4.4)	81 (3.1)	0.008
Heart failure etiology				< 0.001
Ischemic	2,113 (37.6)	1,300 (43.4)	813 (30.9)	
Cardiomyopathy	1,159 (20.6)	661 (22.1)	498 (18.9)	
Valvular heart disease	804 (14.3)	320 (10.7)	484 (18.4)	
Tachycardia-induced	600 (10.7)	273 (9.1)	327 (12.4)	
Hypertensive	222 (3.9)	104 (3.5)	118 (4.5)	
Others	727 (12.9)	335 (11.2)	392 (14.9)	

Values are presented as number (%).

HF_{mr}EF, heart failure with mildly reduced ejection fraction; HF_pEF, heart failure with preserved ejection fraction; HF_rEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction.

with 2,993 (53.2%) being men. Table 1 presents the baseline clinical characteristics of the study population stratified by sex. Women were older and had higher systolic and pulse pressures, along with a higher prevalence of hypertension compared to men. Men, on the other hand, exhibited a higher prevalence of ischemic heart disease, dilated cardiomyopathy, chronic obstructive pulmonary disease, and chronic kidney disease compared to women. According to New York Heart Association (NYHA) classification, women had more severe symptoms compared to men. Men were more likely to be smokers or alcohol drinkers than women. Laboratory results showed that men had higher levels of hemoglobin, uric acid, and C-reactive protein than women.

Conversely, women had more elevated total cholesterol, triglycerides, and N-terminal pro B-type natriuretic peptide (NT-proBNP). In terms of echocardiographic findings, women had a smaller LV volume than men but better LV-EF. Furthermore, women exhibited worse parameters for diastolic function, including LA volume index, e' velocity, E/e ratio, and tricuspid regurgitation V max. These findings suggest a more advanced stage of left ventricular diastolic dysfunction in women compared to men.

Sex-specific HF characteristics

The proportion of HF types differed between men and women. HFrEF was the most prominent type in both men




Figure 1. Types of HF according to age in men and women. (A) Men, (B) Women. HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction.

Table 3. The results of hospitalization

Result	Total (n = 5,625)	Men (n = 2,993)	Women (n = 2,632)	p value
In-hospital mortality	269 (4.8)	157 (5.2)	112 (4.3)	0.082
In-hospital stroke	91 (1.6)	52 (1.7)	39 (1.5)	0.448
Intensive care unit care, yes	2,725 (48.4)	1,531 (51.2)	1,194 (45.4)	< 0.001
Total hospitalization period, days	14.0 ± 17.6	14.3 ± 17.3	13.5 ± 17.8	0.104
Total medical cost during hospitalization, KRW ^{a)}	1,064 ± 2,307	1,199 ± 2,611	910 ± 1,889	< 0.001
Patient co-payment during hospitalization, KRW ^{a)}	334 ± 660	377 ± 758	284 ± 520	< 0.001

Values are expressed as number (%) or mean ± standard deviation.

KRW, Korean won.

^{a)}US \$1 = 1,384 KRW as of November 2022.




Figure 2. In-hospital mortality and intensive care unit admission by sex in HFrEF and HFpEF. (A) In-hospital mortality, (B) Intensive care unit admission. HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction.

Table 4. Clinical characteristics at the time of discharge

Characteristic	Total (n = 5,625)	Men (n = 2,836)	Women (n = 2,520)	p value
Body weight, kg	57.7 ± 13.3	62.8 ± 12.8	51.7 ± 11.2	< 0.001
Systolic blood pressure, mmHg	114.8 ± 17.6	114.4 ± 17.3	115.3 ± 17.9	0.061
Diastolic blood pressure, mmHg	67.0 ± 11.9	67.5 ± 11.7	66.3 ± 11.9	< 0.001
Pulse pressure, mmHg	47.7 ± 14.6	46.7 ± 14.3	48.8 ± 14.8	< 0.001
Heart rate, per minute	76.6 ± 14.6	76.6 ± 14.6	76.6 ± 14.5	0.841
Laboratory findings				
Hemoglobin, g/dL	12.0 ± 2.2	12.4 ± 2.3	11.5 ± 1.8	< 0.001
Glucose, mg/dL	124.0 ± 58.4	123.3 ± 56.9	124.9 ± 60.0	0.315
Uric acid, mg/dL	6.0 ± 3.3	6.2 ± 3.4	5.8 ± 3.1	< 0.001
Creatinine, mg/dL	1.4 ± 1.4	1.6 ± 1.6	1.2 ± 1.0	< 0.001
eGFR, mL/min/1.73 m ²	66.9 ± 40.4	68.7 ± 44.8	64.7 ± 34.6	< 0.001
Sodium, mEq/dL	137.8 ± 4.4	137.7 ± 4.4	138.0 ± 4.4	0.003
Potassium, mEq/dL	4.2 ± 0.5	4.2 ± 0.5	4.2 ± 0.5	< 0.001
C-reactive protein, mg/dL	2.1 ± 3.8	2.4 ± 4.0	1.8 ± 3.5	< 0.001
NT-proBNP, pg/mL	8,738.1 ± 10,565.9	8,017.1 ± 10,099.5	9,544.0 ± 11,011.8	< 0.001
Medications				
RAS blockers	3,708 (65.9)	2,015 (67.3)	1,693 (64.3)	0.018
ACE inhibitors	1,582 (28.1)	926 (30.9)	656 (24.9)	< 0.001
Angiotensin receptor blockers	2,126 (37.8)	1,089 (36.4)	1,037 (39.4)	0.020
Beta-blockers	2,806 (49.9)	1,518 (50.7)	1,288 (48.9)	0.182
Mineralocorticoid receptor antagonist	2,526 (44.9)	1,316 (44.0)	1,210 (46.0)	0.132
Nitrate	1,231 (21.9)	692 (23.1)	539 (20.5)	0.056
Hydralazine	32 (0.6)	19 (0.6)	13 (0.5)	0.639
Loop diuretic	3,991 (71.0)	2,092 (69.9)	1,899 (72.2)	0.004
Digoxin	1,437 (25.5)	753 (25.2)	684 (26.0)	0.773
Amiodarone	422 (7.5)	239 (8.0)	183 (7.0)	0.001

Numbers are expressed as mean ± standard deviation or n (%).

ACE, angiotensin-converting enzyme; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro B-type natriuretic peptide; RAS, renin-angiotensin system.

(65.8%) and women (48.6%), but the proportion of HFpEF was significantly higher in women (31.9% vs. 17.5%), as indicated in Table 2 and Figure 1. Furthermore, there was a higher proportion of elderly patients among women compared to men, as most male patients were in their 60s and 70s, while the majority of female patients were in their 70s and 80s. Men exhibited relatively higher rates of de novo HF and cardiogenic shock. The etiologies of HF showed a similar trend in both men and women, with ischemia being the most common cause. However, the rates of ischemia and cardiomyopathy as HF etiologies were higher in men, whereas the rates of valvular disease, tachycardia, and hypertension were higher in women compared to men.

In-hospital outcomes

As shown in Table 3, there were no significant differences in terms of in-hospital mortality and stroke between men and women. However, the rates of intensive care unit admission and total medical cost were higher in men than in women. These findings did not differ significantly between HFpEF and HFrEF, respectively (Fig. 2).

Discharge profiles

Table 4 shows the laboratory findings at discharge and the medication prescribed to patients. The laboratory findings were similar to those at admission, with low hemoglobin and C-reactive protein and high NT-ProBNP levels in women at discharge. Although women were less likely to receive




Figure 3. Event-free survival curves. The risk of the study outcomes was compared according to the sex. (A) Cardiovascular death, (B) All-cause death, (C) HF readmission, and (D) Composite outcomes. HF, heart failure; HR, hazard ratio.




Figure 4. Event-free survival curves in HFrEF and HFpEF. The risk of the study outcomes was evaluated for men and women in HFrEF and HFpEF, respectively. (A) Cardiovascular death in HFrEF, (B) HF readmission in HFrEF, (C) Composite outcomes in HFrEF, (D) Cardiovascular death in HFpEF, (E) HF readmission in HFpEF, (F) Composite outcomes in HFpEF. HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HR, hazard ratio.

renin-angiotensin system (RAS) blockers in the total population (67.3 vs. 64.3%, $p = 0.018$), there were no significant differences in the rates of guideline-directed medical therapies (GDMTs) for patients with HFrEF between men and women. The prescription rates of RAS blockers (72.6 vs. 72.5%, $p = 0.942$), beta-blockers (53.1 vs. 55.4%, $p = 0.209$), and mineralocorticoid receptor antagonist (MRA) (49.3 vs. 51.8%, $p = 0.162$) were similar in men and

women with HFrEF (Supplementary Table 1). However, loop diuretics were prescribed at a higher rate in women.

Sex differences in long-term outcome

During a median follow-up of 3.4 years (interquartile range, 1.0–4.9 yr), there were 2,685 deaths (47.7%) (1,388 in men [48.9%] and 1,297 in women [51.5%]), including 625 cardiovascular deaths (329 in men and 296 in women), and

Table 5. Independent predictors for composite events of death and heart failure readmission

Variable	HR (95% CI)	<i>p</i> value
Age ≥ 65 yr	1.59 (1.41–1.80)	< 0.001
Male sex	1.14 (1.02–1.28)	0.019
Body mass index ≥ 25 kg/m ²	0.88 (0.79–0.98)	0.016
Hypertension	1.08 (0.97–1.20)	0.156
Diabetes mellitus	1.15 (1.04–1.27)	0.008
Cigarette smoking	0.90 (0.78–1.04)	0.152
Alcohol drinking	0.88 (0.78–0.98)	0.022
Ischemic etiology	1.12 (1.01–1.25)	0.035
Previous heart failure	1.55 (1.40–1.71)	< 0.001
Systolic blood pressure < 100 mmHg	1.24 (1.08–1.44)	0.004
Heart rate ≥ 100 per minute	1.04 (0.94–1.15)	0.424
Sodium < 135 mEq/L	1.23 (1.12–1.37)	< 0.001
Hemoglobin < 12 g/dL	1.24 (1.11–1.37)	< 0.001
Estimated GFR < 60 mL/min/1.73 m ²	1.26 (1.13–1.40)	< 0.001
NT-proBNP > 1,000 pg/dL	1.24 (1.11–1.38)	0.001
RAS blockers	0.89 (0.80–0.99)	0.024
Beta-blockers	0.77 (0.71–0.85)	< 0.001

CI, confidence interval; GFR, glomerular filtration rate; HR, hazard ratio; NT-proBNP, N-terminal pro B-type natriuretic peptide; RAS, renin-angiotensin system.




Figure 5. Association between LV-EF and the risk of the composite outcomes. A spline curve showing the HR for the composite outcomes in (A) whole population, and (B) men and women separately. LV-EF, left ventricular-ejection fraction; HR, hazard ratio.

1,782 HF readmissions (922 in men and 860 in women). In a multivariable analysis, male sex was an independent predictor of cardiovascular death (adjusted HR, 1.38; 95% confidence interval [CI], 1.07–1.78; $p = 0.014$), all-cause death (adjusted HR, 1.37; 95% CI, 1.21–1.56; $p < 0.001$), and the composite outcomes of all-cause death and HF readmission (adjusted HR, 1.13; 95% CI, 1.01–1.27, $p = 0.030$) (Fig. 3A, B, D). However, there was no significant difference in the risk of HF readmission between men and women (adjusted HR, 0.96; 95% CI, 0.83–1.12; $p = 0.962$) (Fig. 3C). When analyzing HFrEF and HFpEF separately, there was no significant difference in the incidence of cardiovascular death (adjusted HR, 1.40; 95% CI, 0.80–2.42; $p = 0.231$) and HF readmission (adjusted HR, 0.94; 95% CI, 0.66–1.33; $p = 0.708$) in HFpEF. However, male sex was an independent risk factor of cardiovascular death (adjusted HR, 1.59; 95% CI, 1.14–2.20; $p = 0.006$) and all-cause death (adjusted HR, 1.41; 95% CI, 1.20–1.67; $p < 0.001$) in patients with HFrEF (Fig. 4).

Risk factors for long-term outcomes in HF

In the total study population, old age, lower BMI, ischemic etiology, previous HF, hyponatremia, anemia, and renal disease were found to be associated with adverse composite outcomes (Table 5). LV-EF was not associated with the composite outcomes (HR, 0.99 per LVEF +10%; 95% CI, 0.97–1.01; $p = 0.230$), and the association between composite outcomes and LV-EF did not differ by sex (p for interaction = 0.099, Fig. 5).

DISCUSSION

In this study, we investigated sex differences in the clinical characteristics and long-term outcomes of Korean patients with acute HF. Women were found to be older and have more severe symptoms, as well as higher levels of NT-proBNP. The proportion of HFpEF was higher in women than in men, and this was supported by findings indicating a more advanced stage of LV diastolic dysfunction in women. In terms of in-hospital outcomes, no significant differences were observed between men and women. Although there was no sex difference in discharge medications, we found that women were associated with a lower risk of the occurrence of composite outcomes, including all-cause death and HF readmission.

Sex differences in baseline clinical characteristics

Diverse previous studies have shown the sex-dependent characteristics of patients with HF [2-7]. Consistently with previous literature [2-7], women are older than men and have a higher prevalence of hypertension and valve diseases in our study. On the other hand, women had a lower prevalence of ischemic heart disease, chronic obstructive pulmonary disease, and chronic kidney disease. Despite symptoms of HF being generally similar between men and women [19], our study revealed that women had worse symptoms based on NYHA classification. Previous literatures have also demonstrated that women with HF tended to have a greater symptom burden, such as dyspnea and more difficulty exercising than men. [9,13,19] The reasons why women experience worse HF-related symptoms than men are still unclear. Several reasons have been suggested. For example, Dewan et al. [13] demonstrated that undertreatment of diuretics considering congestion status might be one of the reasons, and worse renal dysfunction of women in that study was inferred as a relevant cause. Additionally, the higher frequency of obesity in women has also been described as a possible cause of severe symptoms of HF in women [4]. However, in our study, women showed no significant differences in BMI, used more diuretics, and were likely to have better renal function. Other explanations, such as social activities and depression in women might be relevant considering the results of our study. Since women in older age usually engaged in more social activities than men, such as participating in community activities, meeting friends, and visiting relatives, it can be suggested that reducing social activities due to HF symptoms may worsen quality of life [20].

Sex-specific prevalence of HFrEF and HFpEF

Earlier investigations have suggested that women were more susceptible to HFpEF than men [21-24]. However, recent research has revealed that the increased occurrence of HFpEF may be related to age distribution rather than sex-related differences in pathophysiology [25]. In accordance with this, our study found that the proportion of female patients increased after the age of 70–80 years, and the proportion of HFpEF also increased after the age of 70 (Fig. 1). There were more women than men in our registry among the elderly, which may have contributed to the higher number of women with high HFpEF ratios. In addition, women showed

more advanced findings in diastolic function indicators. Despite the higher EF in women, their e' velocity was lower, E/e' and pulmonary artery systolic pressure were higher, and LA size was greater than in men. These findings align with the higher proportion of HFpEF in women. All these diastolic parameters were significantly correlated with age, supporting the idea that large number of women among older patients may have had an effect on advanced diastolic function in women.

Sex difference in short-term and long-term prognosis

Previous studies have indicated that women had better survival rates than men across a broad spectrum of HF [9,26-28]. However, studies focused on short-term mortality or in-hospital mortality have found no differences based on sex [14,29]. In our study, we found no sex differences in in-hospital mortality and length of hospital stay, although men had higher costs and higher rates of intensive care unit admission. Similar trends were observed when HFpEF and HFrEF were analyzed separately. These results differ slightly from the long-term outcome, which may be due to differences between the factors that lead to the acute event and those that determine mid-term or long-term mortality or hospitalization. In-hospital mortality is relatively rare, and factors such as vital signs at the time of hospitalization may have a greater impact than sex differences [29].

Regarding long-term outcomes, our study found that women were at a lower risk of a composite outcomes than men due to a substantially lower risk of cardiovascular and all-cause death in our study. Several factors have been suggested to explain why women have a better prognosis, and one possible explanation is the differences in the prevalence of ischemic heart disease. Consistent with previous literature, our findings showed that ischemic heart disease is more common in men [4,9]. In fact, ischemic heart disease was present in 45.6% of male patients with cardiovascular death, but only 33.1% of female patients. A previous study suggested that women have a less atherosclerotic burden and fewer plaque rupture than men in the setting of acute coronary syndrome [30]. The increased prevalence of cardiovascular death in men aligns with the relationship between ischemic heart disease and sudden cardiac death. Another study found that men with ischemic heart diseases who had an implantable cardioverter defibrillator experienced more ventricular arrhythmias than women [31,32]. The differenc-

es in sensitivity to ventricular arrhythmias may account for sex differences in sudden cardiac death rates. Given that the main differences in this study were in cardiovascular mortality, the disparity in the prevalence of ischemic heart disease between men and women may be one of the important explanations.

Hospitalization for HF is an important issue as it significantly increases patient morbidity and mortality. Decompensated HF with impaired recovery is associated with a poor prognosis [33]. Generally, the prognosis of HF is known to be better in women, but a recent study reported a higher readmission rate for women [8]. However, another study reported no sex differences in readmission rate [9], and our study also found no sex difference in HF readmission rates between men and women. The factors affecting HF readmission in our study were age and history of HF, which were not modifiable factors. Thus, reducing the readmission rate in HF requires new strategies, and, several approaches have recently been proposed [34]. Since there is no sex difference in the readmission rate in HF, new strategies that can be applied well to both men and women should be developed.

The majority of research examining sex differences in the characteristics and prognostic outcomes of HF has predominantly centered on Western populations [6,8,9,13,14,35]. Our study, along with the Japanese study [5,7], has confirmed that sex differences in HF among Asians do not exhibit a significant distinction from those observed in Western populations. Both Asian and Western populations demonstrate similar trends in terms of sex distribution and underlying conditions in relation to HF. In addition, although there are differences among studies, there is no clear difference between the East and the West in terms of HF prognosis. This consistent pattern between Asians and Westerners highlights the importance of sex-specific considerations in HF management and treatment strategies.

There are several limitations to this study. Data regarding medication changes during clinical follow-up was unavailable, which prevented us from evaluating the impact of discontinuation or initiation of drugs. Previous literature has reported that sacubitril/valsartan reduced HF hospitalization and functional improvement in women patients [36,37]. During the period of inclusion in this study, sacubitril/valsartan was not available in Korea, but it is possible that this medication was administered during the patients' follow-up period and could have influenced the results. Additionally, because only tertiary hospitals participated in this registry,

our cohort might not accurately reflect the overall population of HF in Korea.

Conclusions

In this real-world registry of Korean patients with acute HF, significant sex differences were observed in clinical features and long-term outcomes. Men were found to be an independent predictor of composite outcomes, despite the fact that women were older, had more severe symptoms, and higher levels of NT-proBNP. These discrepancies were mainly caused by cardiovascular death in patients with HF_rEF.

KEY MESSAGE

1. Women were older and presented with more severe symptoms and higher levels of NT-proBNP. Both men and women predominantly presented with HF_rEF. However, it was observed that women had a significantly higher proportion of HF_pEF compared to men.
2. Men were identified as independent predictors of cardiovascular death and HF readmission. The discrepancies in HF prognosis between sexes were primarily attributed to cardiovascular death in patients with HF_rEF.

REFERENCES

1. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. *Eur J Heart Fail* 2020;22:1342-1356.
2. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. *Cardiovasc Res* 2023;118:3272-3287.
3. Lam CSP, Arnott C, Beale AL, et al. Sex differences in heart failure. *Eur Heart J* 2019;40:3859-3868c.
4. Postigo A, Martínez-Sellés M. Sex influence on heart failure prognosis. *Front Cardiovasc Med* 2020;7:616273.
5. Sakai T, Motoki H, Suzuki S, et al. Gender difference in heart failure with preserved ejection fraction: clinical profiles, examinations, and prognosis. *Heart Vessels* 2022;37:1710-1718.
6. Gimeno-Miguel A, Gracia Gutiérrez A, Poblador-Plou B, et al. Multimorbidity patterns in patients with heart failure: an observational Spanish study based on electronic health records. *BMJ Open* 2019;9:e033174.
7. Sakata Y, Miyata S, Nochioka K, et al. Gender differences in clinical characteristics, treatment and long-term outcome in patients with stage C/D heart failure in Japan. Report from the CHART-2 study. *Circ J* 2014;78:428-435.
8. López-Vilella R, Marqués-Sulé E, Laymito Quispe RDP, et al. The female sex confers different prognosis in heart failure: same mortality but more readmissions. *Front Cardiovasc Med* 2021;8:618398.
9. Deswal A, Bozkurt B. Comparison of morbidity in women versus men with heart failure and preserved ejection fraction. *Am J Cardiol* 2006;97:1228-1231.
10. Ghali JK, Krause-Steinrauf HJ, Adams KF, et al. Gender differences in advanced heart failure: insights from the BEST study. *J Am Coll Cardiol* 2003;42:2128-2134.
11. O'Meara E, Clayton T, McEntegart MB, et al.; CHARM Investigators. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. *Circulation* 2007;115:3111-3120.
12. Lam CS, Carson PE, Anand IS, et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. *Circ Heart Fail* 2012;5:571-578.
13. Dewan P, Rørth R, Raparelli V, et al. Sex-related differences in heart failure with preserved ejection fraction. *Circ Heart Fail* 2019;12:e006539.
14. Santas E, Palau P, Llácer P, et al. Sex-related differences in mortality following admission for acute heart failure across the left ventricular ejection fraction spectrum. *J Am Heart Assoc* 2022;11:e022404.
15. Sotomi Y, Hikoso S, Nakatani D, et al.; PURSUIT-HFpEF Investigators. Sex differences in heart failure with preserved ejection fraction. *J Am Heart Assoc* 2021;10:e018574.
16. Chung J, Kim HL, Kim MA, et al. Sex differences in long-term clinical outcomes in patients hospitalized for acute heart failure: a report from the Korean heart failure registry. *J Womens Health (Larchmt)* 2019;28:1606-1613.
17. Lee SE, Lee HY, Cho HJ, et al. Clinical characteristics and outcome of acute heart failure in Korea: results from the Korean Acute Heart Failure Registry (KorAHF). *Korean Circ J* 2017;47:341-353.
18. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by

- echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2016;29:277-314.
19. Eisenberg E, Di Palo KE, Piña IL. Sex differences in heart failure. *Clin Cardiol* 2018;41:211-216.
 20. Riedinger MS, Dracup KA, Brecht ML; SOLVD Investigators. Studies of Left Ventricular Dysfunction. Quality of life in women with heart failure, normative groups, and patients with other chronic conditions. *Am J Crit Care* 2002;11:211-219.
 21. Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. *Ann Intern Med* 2002;137:631-639.
 22. Bursi F, Weston SA, Redfield MM, et al. Systolic and diastolic heart failure in the community. *JAMA* 2006;296:2209-2216.
 23. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. *N Engl J Med* 2006;355:251-259.
 24. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC; ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. *J Am Coll Cardiol* 2006;47:76-84.
 25. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. *Nat Rev Cardiol* 2017;14:591-602.
 26. Adams KF Jr, Sueta CA, Gheorghiade M, et al. Gender differences in survival in advanced heart failure. Insights from the FIRST study. *Circulation* 1999;99:1816-1821.
 27. Piña IL. A better survival for women with heart failure? It's not so simple... *J Am Coll Cardiol* 2003;42:2135-2138.
 28. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. *JAMA* 2004;292:344-350.
 29. Hsich EM, Grau-Sepulveda MV, Hernandez AF, et al. Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction. *Am Heart J* 2012;163:430-437, 437.e1-e3.
 30. Lansky AJ, Ng VG, Maehara A, et al. Gender and the extent of coronary atherosclerosis, plaque composition, and clinical outcomes in acute coronary syndromes. *JACC Cardiovasc Imaging* 2012;5(3 Suppl):S62-S72.
 31. Lampert R, McPherson CA, Clancy JF, Caulin-Glaser TL, Rosenfeld LE, Batsford WP. Gender differences in ventricular arrhythmia recurrence in patients with coronary artery disease and implantable cardioverter-defibrillators. *J Am Coll Cardiol* 2004;43:2293-2299.
 32. MacFadden DR, Crystal E, Krahn AD, et al. Sex differences in implantable cardioverter-defibrillator outcomes: findings from a prospective defibrillator database. *Ann Intern Med* 2012;156:195-203.
 33. Böhm M, Komajda M, Borer JS, et al.; SHIFT Investigators. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. *Eur J Heart Fail* 2018;20:373-381.
 34. Diamond J, DeVore AD. New strategies to prevent rehospitalizations for heart failure. *Curr Treat Options Cardiovasc Med* 2022;24:199-212.
 35. Russo G, Rea F, Barbati G, et al. Sex-related differences in chronic heart failure: a community-based study. *J Cardiovasc Med (Hagerstown)* 2021;22:36-44.
 36. Vicent L, Ayesta A, Esteban-Fernández A, et al. Sex influence on the efficacy and safety of sacubitril/valsartan. *Cardiology* 2019;142:73-78.
 37. McMurray JJV, Jackson AM, Lam CSP, et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. *Circulation* 2020;141:338-351.

Received : July 7, 2023
 Revised : August 21, 2023
 Accepted : September 8, 2023

Correspondence to
 Myung-A Kim, M.D., Ph.D.
 Division of Cardiology, Department of Internal Medicine, Boramae Medical Center, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Korea
 Tel: +82-2-870-2213, Fax: +82-2-870-3866
 E-mail: kma@snu.ac.kr
<https://orcid.org/0000-0002-3064-7118>

Acknowledgements
 These authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. KorAHF Investigators: Byung-Hee Oh, Myeong-Chan Cho, Jae-Joong Kim, Sang Hong Baek, Eun-Seok Jeon, Dong-Ju Choi, Youngkeun Ahn, Byung-Su Yoo, Seok-Min Kang, Shung Chull Chae, Hae-Young Lee, Hyun-Jai Cho, Kye Hun Kim, Jin-Oh Choi, Kyung-Kuk Hwang, Min-Seok Kim, Suk Min Seo, Jin Joo Park, Sang Eun Lee, Jae Yeong Cho, Se Yong Jang, Ju Hee Lee, Jaewon Oh.

Credit authorship contributions
 Hyue Mee Kim: investigation, formal analysis, writing - original draft; Hack-Lyoung Kim: conceptualization, investigation, formal analysis,

writing - original draft; Myung-A Kim: conceptualization, investigation, writing - review & editing; Hae-Young Lee: methodology, writing - review & editing; Jin Joo Park: methodology, writing - review & editing; Dong-Ju Choi: methodology, writing - review & editing

Conflicts of interest

The authors disclose no conflicts.

Funding

None

Supplementary Table 1. Medication at discharge according to the type of heart failure

Medication	Men	Women	<i>p</i> value
HFrEF			
RAS blockers	1,432 (72.6)	928 (72.5)	0.942
ACE inhibitors	727 (36.9)	404 (31.6)	0.002
Angiotensin receptor blockers	705 (35.8)	524 (40.9)	0.003
Beta-blockers	1,048 (53.1)	709 (55.4)	0.209
Mineralocorticoid receptor antagonist	972 (49.3)	663 (51.8)	0.162
Nitrate	490 (24.8)	313 (24.5)	0.8867
Hydralazine	13 (0.7)	9 (0.7)	0.619
Loop diuretic	1,471 (74.6)	976 (76.0)	0.154
Digoxin	583 (29.6)	379 (29.6)	0.931
Amiodarone	181 (9.2)	84 (6.6)	0.002
Non HFrEF (HFmrEF, HFpEF)			
RAS blockers	525 (57.4)	728 (58.3)	0.678
ACE inhibitors	181 (19.8)	242 (19.4)	0.811
Angiotensin receptor blockers	344 (37.6)	486 (38.9)	0.537
Beta-blockers	432 (47.3)	546 (43.8)	0.105
Mineralocorticoid receptor antagonist	318 (34.8)	505 (40.5)	0.007
Nitrate	178 (19.5)	203 (16.3)	0.125
Hydralazine	6 (0.7)	4 (0.3)	0.513
Loop diuretic	555 (60.7)	859 (66.8)	< 0.001
Digoxin	157 (17.2)	285 (22.8)	0.001
Amiodarone	44 (4.8)	88 (7.1)	0.077

Values are presented as number (%).

ACE, angiotensin-converting enzyme; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; RAS, renin-angiotensin system.